| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000031670 |
| Receipt No. | R000036171 |
| Official scientific title of the study | A prospective cohort study of neoadjuvant chemotherapy using carboplatin and dose dense paclitaxel for locally advanced cervical cancer |
| Date of disclosure of the study information | 2018/03/12 |
| Last modified on | 2018/03/11 (Ver. 1) |
| Basic information | ||
| Official scientific title of the study | A prospective cohort study of neoadjuvant chemotherapy using carboplatin and dose dense paclitaxel for locally advanced cervical cancer | |
| Title of the study (Brief title) | CC-NAC | |
| Region |
|
|
| Condition | ||
| Condition | Cervical cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To assess the efficacy and safety of neoadjuvant chemotherapy using dose dense TC therapy for patients with locally advanced cervical cancer.
To investigate the pathological mapping of residual tumor after nepoadjuvant chemotherapy. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 2-year progression free survival rate |
| Key secondary outcomes | Response rate
Pathological complete response rate 2-year overall survival Toxicity Site of recurrence Completion rate of neoadjuvant chemotherapy Pathological mapping of residual tumor Imaging findings of residual tumor |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | expanded access |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | dose dense TC therapy (Carboplatin AUC =6 Day1 + Paclitaxel 80mg/m2 Day1, 8, 15) 3 weeks interval
3 cycles before surgery |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1. Pathologically confirmed cervical cancer.
2. FIGO stage Ib2, IIa2, IIb 3. ECOG PS =0 to 2 4. Patients with adequate function of principal organs. 5. Patients expected to live more than 3 months. 6. Patients older than 20 years. 7. Patients with informed consent. |
|||
| Key exclusion criteria | 1. Patients with previous radiation therapy.
2. Any active double cancers. 3. Patients with any serious complications. 4. Patients with hypersensitivity to castor ail. 5. Patients with hypersensitivity to alcohol. 6. Carrier of HBV or HCV. 7. Patients with active infection which needs antibiotics. 8. Patients with interstitial pneumonia. 9. Pregnant woman. 10. Patients regard to be inadequate for entering this study. |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Shoji Nagao |
| Organization | Hyogo Cancer Center |
| Division name | Gynecologic Oncology |
| Address | 13-70 Kitaoji-cho, Akashi-city |
| TEL | 078-929-1151 |
| nagao@hp.pref.hyogo.jp | |
| Public contact | |
| Name of contact person | Kazuhiro Suzuki |
| Organization | Hyogo Cancer Center |
| Division name | Gynecologic Oncology |
| Address | 13-70 Kitaoji-cho, Akashi-city |
| TEL | 078-929-1151 |
| Homepage URL | |
| kazuhi-suzuki@hyogo-cc.jp | |
| Sponsor | |
| Institute | Hyogo Cancer Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Hyogo Cancer Center |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036171 |